SEC Filing Summary: Wound Management Technologies, Inc. (10-K)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2009. Wound Management Technologies, Inc. (WMT) is a smaller reporting company focused on the distribution of CellerateRX, a patented collagen-based wound care product. The company operates through wholly-owned subsidiaries, including Wound Care Innovations, LLC (WCI), Resorbable Orthopedic Products, LLC, and BioPharma Management Technologies, Inc. (acquired in September 2009). WMT does not own manufacturing facilities; production is outsourced to Applied Nutritionals, LLC.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenues | $288,021 | $290,183 |
| Cost of Revenues | $1,105,228 | $417,099 |
| Gross Profit (Loss) | $(817,207) | $(126,916) |
| Net Loss | $(2,302,527) | $(1,773,196) |
| Cash and Cash Equivalents (End of Period) | $(4,363) | $1,142 |
| Total Assets | $4,772,597 | $151,714 |
| Total Liabilities | $2,457,610 | $472,971 |
| Stockholders' Equity (Deficiency) | $2,314,987 | $(321,257) |
Note: The company reported a negative cash balance of $(4,363) at year-end, indicating an overdraft or bank loan balance.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased slightly by 0.75% to $288,021.
- Cost of Revenue Surge: Costs of revenues increased 165% to $1.1 million. This was primarily driven by a $600,000 royalty expense related to the CellerateRX license agreement (including a $400,000 advance royalty and accrued minimums), which was not present in 2008.
- Operating Expenses: General and administrative (G&A) expenses decreased 44% to $900,109, largely due to reduced consulting fees.
- Interest Expense: Interest expense increased 389% to $473,278 due to increased debt levels.
- Acquisitions: The company recorded significant intangible assets ($4.65 million total) from the acquisition of BioPharma (marketing rights) and Resorbable (patent), funded primarily by issuing 5 million shares of common stock.
Outlook, Risks, and Contingencies
- Going Concern: The independent auditors issued a "going concern" qualification. The company has incurred substantial losses, has a working capital deficit, and requires additional financing to continue operations. There is no assurance that capital can be raised.
- Liquidity: The company ended 2009 with a negative cash balance. Financing activities generated approximately $1.3 million during the year, but the company anticipates needing more capital in 2010.
- Contractual Obligations: As of December 31, 2009, the company owed $383,013 in unpaid royalties. Additionally, there is a delinquent federal payroll tax liability of approximately $203,484 plus penalties and interest of $183,796, against which a tax lien was filed in December 2009.
- Legal Proceedings: The company is defending a Florida state court lawsuit regarding alleged nonpayment of brokerage commissions. A prior federal lawsuit regarding 1997 share issuances was dismissed in June 2009.
- Future Strategy: Management plans to expand into international markets (Middle East, Europe, Mexico) via new distribution agreements and launch orthopedic products in late 2010. They also acquired Secure eHealth technology assets in February 2010.
Investor Verification Checklist
- Cash Position: Verify the status of the negative cash balance and the company's ability to secure immediate working capital.
- Royalty Obligations: Confirm the payment status of the $383,013 accrued royalty liability and the $375,000 annual minimum royalty requirement.
- Tax Liens: Investigate the resolution status of the IRS tax lien filed in December 2009 regarding unpaid payroll taxes.
- Revenue Concentration: Note that 4 customers accounted for over 10% of revenue each in 2009, representing 45% of total accounts receivable.
- Stock Dilution: Review the impact of recent stock issuances (5 million shares in 2009 for acquisitions) on existing shareholder equity.